Pre-treatment calprotectin (MRP8/14) provides no added value to testing CRP alone in terms of predicting response to TNF inhibitors in rheumatoid arthritis in a post hoc analysis

OBJECTIVES: The inflammatory protein calprotectin (MRP8/14) has been identified as a promising biomarker of treatment response in rheumatoid arthritis (RA). Our aim was to test MRP8/14 as a biomarker of response to tumour necrosis factor (TNF)-inhibitors in the largest RA cohort to date and to compa...

Descripción completa

Detalles Bibliográficos
Autores principales: Smith, Samantha Louise, Alexander, Sheree, Nair, Nisha, Viatte, Sebastien, Eyre, Stephen, Hyrich, Kimme L, Morgan, Ann W, Wilson, Anthony G, Isaacs, John D, Plant, Darren, Barton, Anne
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Rheumatoid Arthritis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10176427/
https://www.ncbi.nlm.nih.gov/pubmed/36810200
http://dx.doi.org/10.1136/ard-2022-222519

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10176427/
https://www.ncbi.nlm.nih.gov/pubmed/36810200
http://dx.doi.org/10.1136/ard-2022-222519

Ejemplares similares